@article{DornelasAntaoMoyesetal.2018,
  author    = {Dornelas, Maria and Ant{\~a}o, Laura H. and Moyes, Faye and Bates, Amanda E. and Magurran, Anne E. and Adam, Dušan and Akhmetzhanova, Asem A. and Appeltans, Ward and Arcos, Jos{\´e} Manuel and Arnold, Haley and Ayyappan, Narayanan and Badihi, Gal and Baird, Andrew H. and Barbosa, Miguel and Barreto, Tiago Egydio and B{\"a}ssler, Claus and Bellgrove, Alecia and Belmaker, Jonathan and Benedetti-Cecchi, Lisandro and Bett, Brian J. and Bjorkman, Anne D. and Błażewicz, Magdalena and Blowes, Shane A. and Bloch, Christopher P. Bloch and Bonebrake, Timothy C. and Boyd, Susan and Bradford, Matt and Brooks, Andrew J. and Brown, James H. and Bruelheide, Helge and Budy, Phaedra and Carvalho, Fernando and Casta{\~n}eda-Moya, Edward and Chen, Chaolun Allen and Chamblee, John F. and Chase, Tory J. and Siegwart Collier, Laura and Collinge, Sharon K. and Condit, Richard and Cooper, Elisabeth J. and Cornelissen, J. Hans C. and Cotano, Unai and Crow, Shannan Kyle and Damasceno, Gabriella and Davies, Claire H. and Davis, Robert A. and Day, Frank P. and Degraer, Steven and Doherty, Tim S. and Dunn, Timothy E. and Durigan, Giselda and Duffy, J. Emmett and Edelist, Dor and Edgar, Graham J. and Elahi, Robin and Elmendorf, Sarah C. and Enemar, Anders and Ernest, S. K. Morgan and Escribano, Rub{\´e}n and Estiarte, Marc and Evans, Brian S. and Fan, Tung-Yung and Turini Farah, Fabiano and Loureiro Fernandes, Luiz and Farneda, F{\´a}bio Z. and Fidelis, Alessandra and Fitt, Robert and Fosaa, Anna Maria and Franco, Geraldo Antonio Daher Correa and Frank, Grace E. and Fraser, William R. and Garc{\´i}a, Hernando and Cazzolla Gatti, Roberto and Givan, Or and Gorgone-Barbosa, Elizabeth and Gould, William A. and Gries, Corinna and Grossman, Gary D. and Gutierr{\´e}z, Julio R. and Hale, Stephen and Harmon, Mark E. and Harte, John and Haskins, Gary and Henshaw, Donald L. and Hermanutz, Luise and Hidalgo, Pamela and Higuchi, Pedro and Hoey, Andrew and Van Hoey, Gert and Hofgaard, Annika and Holeck, Kristen and Hollister, Robert D. and Holmes, Richard and Hoogenboom, Mia and Hsieh, Chih-hao and Hubbell, Stephen P. and Huettmann, Falk and Huffard, Christine L. and Hurlbert, Allen H. and Ivanauskas, Nat{\´a}lia Macedo and Jan{\´i}k, David and Jandt, Ute and Jażdżewska, Anna and Johannessen, Tore and Johnstone, Jill and Jones, Julia and Jones, Faith A. M. and Kang, Jungwon and Kartawijaya, Tasrif and Keeley, Erin C. and Kelt, Douglas A. and Kinnear, Rebecca and Klanderud, Kari and Knutsen, Halvor and Koenig, Christopher C. and Kortz, Alessandra R. and Kr{\´a}l, Kamil and Kuhnz, Linda A. and Kuo, Chao-Yang and Kushner, David J. and Laguionie-Marchais, Claire and Lancaster, Lesley T. and Lee, Cheol Min and Lefcheck, Jonathan S. and L{\´e}vesque, Esther and Lightfoot, David and Lloret, Francisco and Lloyd, John D. and L{\´o}pez-Baucells, Adri{\`a} and Louzao, Maite and Madin, Joshua S. and Magn{\´u}sson, Borgþ{\´o}r and Malamud, Shahar and Matthews, Iain and McFarland, Kent P. and McGill, Brian and McKnight, Diane and McLarney, William O. and Meador, Jason and Meserve, Peter L. and Metcalfe, Daniel J. and Meyer, Christoph F. J. and Michelsen, Anders and Milchakova, Nataliya and Moens, Tom and Moland, Even and Moore, Jon and Moreira, Carolina Mathias and M{\"u}ller, J{\"o}rg and Murphy, Grace and Myers-Smith, Isla H. and Myster, Randall W. and Naumov, Andrew and Neat, Francis and Nelson, James A. and Nelson, Michael Paul and Newton, Stephen F. and Norden, Natalia and Oliver, Jeffrey C. and Olsen, Esben M. and Onipchenko, Vladimir G. and Pabis, Krzysztof and Pabst, Robert J. and Paquette, Alain and Pardede, Sinta and Paterson, David M. and P{\´e}lissier, Rapha{\"e}l and Pe{\~n}uelas, Josep and P{\´e}rez-Matus, Alejandro and Pizarro, Oscar and Pomati, Francesco and Post, Eric and Prins, Herbert H. T. and Priscu, John C. and Provoost, Pieter and Prudic, Kathleen L. and Pulliainen, Erkki and Ramesh, B. R. and Ramos, Olivia Mendivil and Rassweiler, Andrew and Rebelo, Jose Eduardo and Reed, Daniel C. and Reich, Peter B. and Remillard, Suzanne M. and Richardson, Anthony J. and Richardson, J. Paul and van Rijn, Itai and Rocha, Ricardo and Rivera-Monroy, Victor H. and Rixen, Christian and Robinson, Kevin P. and Rodrigues, Ricardo Ribeiro and de Cerqueira Rossa-Feres, Denise and Rudstam, Lars and Ruhl, Henry and Ruz, Catalina S. and Sampaio, Erica M. and Rybicki, Nancy and Rypel, Andrew and Sal, Sofia and Salgado, Beatriz and Santos, Flavio A. M. and Savassi-Coutinho, Ana Paula and Scanga, Sara and Schmidt, Jochen and Schooley, Robert and Setiawan, Fakhrizal and Shao, Kwang-Tsao and Shaver, Gaius R. and Sherman, Sally and Sherry, Thomas W. and Siciński, Jacek and Sievers, Caya and da Silva, Ana Carolina and da Silva, Fernando Rodrigues and Silveira, Fabio L. and Slingsby, Jasper and Smart, Tracey and Snell, Sara J. and Soudzilovskaia, Nadejda A. and Souza, Gabriel B. G. and Souza, Flaviana Maluf and Souza, Vin{\´i}cius Castro and Stallings, Christopher D. and Stanforth, Rowan and Stanley, Emily H. and Sterza, Jos{\´e} Mauro and Stevens, Maarten and Stuart-Smith, Rick and Suarez, Yzel Rondon and Supp, Sarah and Tamashiro, Jorge Yoshio and Tarigan, Sukmaraharja and Thiede, Gary P. and Thorn, Simon and Tolvanen, Anne and Toniato, Maria Teresa Zugliani and Totland, {\O}rjan and Twilley, Robert R. and Vaitkus, Gediminas and Valdivia, Nelson and Vallejo, Martha Isabel and Valone, Thomas J. and Van Colen, Carl and Vanaverbeke, Jan and Venturoli, Fabio and Verheye, Hans M. and Vianna, Marcelo and Vieira, Rui P. and Vrška, Tom{\´a}š and Vu, Con Quang and Vu, Lien Van and Waide, Robert B. and Waldock, Conor and Watts, Dave and Webb, Sara and Wesołowski, Tomasz and White, Ethan P. and Widdicombe, Claire E. and Wilgers, Dustin and Williams, Richard and Williams, Stefan B. and Williamson, Mark and Willig, Michael R. and Willis, Trevor J. and Wipf, Sonja and Woods, Kerry D. and Woehler, Eric J. and Zawada, Kyle and Zettler, Michael L.},
  title     = {BioTIME: A database of biodiversity time series for the Anthropocene},
  series = {Global Ecology and Biogeography},
  volume    = {27},
  journal   = {Global Ecology and Biogeography},
  doi       = {10.1111/geb.12729},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-222846},
  pages     = {760-786},
  year      = {2018},
  abstract  = {Motivation The BioTIME database contains raw data on species identities and abundances in ecological assemblages through time. These data enable users to calculate temporal trends in biodiversity within and amongst assemblages using a broad range of metrics. BioTIME is being developed as a community-led open-source database of biodiversity time series. Our goal is to accelerate and facilitate quantitative analysis of temporal patterns of biodiversity in the Anthropocene. Main types of variables included The database contains 8,777,413 species abundance records, from assemblages consistently sampled for a minimum of 2 years, which need not necessarily be consecutive. In addition, the database contains metadata relating to sampling methodology and contextual information about each record. Spatial location and grain BioTIME is a global database of 547,161 unique sampling locations spanning the marine, freshwater and terrestrial realms. Grain size varies across datasets from 0.0000000158 km2 (158 cm2) to 100 km2 (1,000,000,000,000 cm2). Time period and grain BioTIME records span from 1874 to 2016. The minimal temporal grain across all datasets in BioTIME is a year. Major taxa and level of measurement BioTIME includes data from 44,440 species across the plant and animal kingdoms, ranging from plants, plankton and terrestrial invertebrates to small and large vertebrates. Software format .csv and .SQL.},
  language  = {en}
}
@article{TranGiaDenisBacelarFerreiraetal.2023,
  author    = {Tran-Gia, Johannes and Denis-Bacelar, Ana M. and Ferreira, Kelley M. and Robinson, Andrew P. and Bobin, Christophe and Bonney, Lara M. and Calvert, Nicholas and Collins, Sean M. and Fenwick, Andrew J. and Finocchiaro, Domenico and Fioroni, Federica and Giannopoulou, Katerina and Grassi, Elisa and Heetun, Warda and Jewitt, Stephanie J. and Kotzasarlidou, Maria and Ljungberg, Michael and Louren{\c{c}}o, Val{\´e}rie and McGowan, Daniel R. and Mewburn-Crook, Jamie and Sabot, Benoit and Scuffham, James and Sj{\"o}green Gleisner, Katarina and Solc, Jaroslav and Thiam, Cheick and Tipping, Jill and Wevrett, Jill and Lassmann, Michael},
  title     = {On the use of solid 133Ba sources as surrogate for liquid 131I in SPECT/CT calibration: a European multi-centre evaluation},
  series = {EJNMMI Physics},
  volume    = {10},
  journal   = {EJNMMI Physics},
  organization    = {The MRT Dosimetry Collaboration},
  doi       = {10.1186/s40658-023-00582-3},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-357740},
  year      = {2023},
  abstract  = {Introduction Commissioning, calibration, and quality control procedures for nuclear medicine imaging systems are typically performed using hollow containers filled with radionuclide solutions. This leads to multiple sources of uncertainty, many of which can be overcome by using traceable, sealed, long-lived surrogate sources containing a radionuclide of comparable energies and emission probabilities. This study presents the results of a quantitative SPECT/CT imaging comparison exercise performed within the MRTDosimetry consortium to assess the feasibility of using 133Ba as a surrogate for 131I imaging. Materials and methods Two sets of four traceable 133Ba sources were produced at two National Metrology Institutes and encapsulated in 3D-printed cylinders (volume range 1.68-107.4 mL). Corresponding hollow cylinders to be filled with liquid 131I and a mounting baseplate for repeatable positioning within a Jaszczak phantom were also produced. A quantitative SPECT/CT imaging comparison exercise was conducted between seven members of the consortium (eight SPECT/CT systems from two major vendors) based on a standardised protocol. Each site had to perform three measurements with the two sets of 133Ba sources and liquid 131I. Results As anticipated, the 131I pseudo-image calibration factors (cps/MBq) were higher than those for 133Ba for all reconstructions and systems. A site-specific cross-calibration reduced the performance differences between both radionuclides with respect to a cross-calibration based on the ratio of emission probabilities from a median of 12-1.5\%. The site-specific cross-calibration method also showed agreement between 133Ba and 131I for all cylinder volumes, which highlights the potential use of 133Ba sources to calculate recovery coefficients for partial volume correction. Conclusion This comparison exercise demonstrated that traceable solid 133Ba sources can be used as surrogate for liquid 131I imaging. The use of solid surrogate sources could solve the radiation protection problem inherent in the preparation of phantoms with 131I liquid activity solutions as well as reduce the measurement uncertainties in the activity. This is particularly relevant for stability measurements, which have to be carried out at regular intervals.},
  language  = {en}
}
@article{TranGiaDenisBacelarFerreiraetal.2021,
  author    = {Tran-Gia, Johannes and Denis-Bacelar, Ana M. and Ferreira, Kelley M. and Robinson, Andrew P. and Calvert, Nicholas and Fenwick, Andrew J. and Finocchiaro, Domenico and Fioroni, Federica and Grassi, Elisa and Heetun, Warda and Jewitt, Stephanie J. and Kotzassarlidou, Maria and Ljungberg, Michael and McGowan, Daniel R. and Scott, Nathaniel and Scuffham, James and Gleisner, Katarina Sj{\"o}green and Tipping, Jill and Wevrett, Jill and Lassmann, Michael},
  title     = {A multicentre and multi-national evaluation of the accuracy of quantitative Lu-177 SPECT/CT imaging performed within the MRTDosimetry project},
  series = {EJNMMI Physics},
  volume    = {8},
  journal   = {EJNMMI Physics},
  doi       = {10.1186/s40658-021-00397-0},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-270380},
  year      = {2021},
  abstract  = {Purpose Patient-specific dosimetry is required to ensure the safety of molecular radiotherapy and to predict response. Dosimetry involves several steps, the first of which is the determination of the activity of the radiopharmaceutical taken up by an organ/lesion over time. As uncertainties propagate along each of the subsequent steps (integration of the time-activity curve, absorbed dose calculation), establishing a reliable activity quantification is essential. The MRTDosimetry project was a European initiative to bring together expertise in metrology and nuclear medicine research, with one main goal of standardizing quantitative \(^{177}\)Lu SPECT/CT imaging based on a calibration protocol developed and tested in a multicentre inter-comparison. This study presents the setup and results of this comparison exercise. Methods The inter-comparison included nine SPECT/CT systems. Each site performed a set of three measurements with the same setup (system, acquisition and reconstruction): (1) Determination of an image calibration for conversion from counts to activity concentration (large cylinder phantom), (2) determination of recovery coefficients for partial volume correction (IEC NEMA PET body phantom with sphere inserts), (3) validation of the established quantitative imaging setup using a 3D printed two-organ phantom (ICRP110-based kidney and spleen). In contrast to previous efforts, traceability of the activity measurement was required for each participant, and all participants were asked to calculate uncertainties for their SPECT-based activities. Results Similar combinations of imaging system and reconstruction lead to similar image calibration factors. The activity ratio results of the anthropomorphic phantom validation demonstrate significant harmonization of quantitative imaging performance between the sites with all sites falling within one standard deviation of the mean values for all inserts. Activity recovery was underestimated for total kidney, spleen, and kidney cortex, while it was overestimated for the medulla. Conclusion This international comparison exercise demonstrates that harmonization of quantitative SPECT/CT is feasible when following very specific instructions of a dedicated calibration protocol, as developed within the MRTDosimetry project. While quantitative imaging performance demonstrates significant harmonization, an over- and underestimation of the activity recovery highlights the limitations of any partial volume correction in the presence of spill-in and spill-out between two adjacent volumes of interests.},
  language  = {en}
}
@article{WestburyTurroGreeneetal.2015,
  author    = {Westbury, Sarah K and Turro, Ernest and Greene, Daniel and Lentaigne, Claire and Kelly, Anne M and Bariana, Tadbir K and Simeoni, Ilenia and Pillois, Xavier and Attwood, Antony and Austin, Steve and Jansen, Sjoert BG and Bakchoul, Tamam and Crisp-Hihn, Abi and Erber, Wendy N and Favier, R{\´e}mi and Foad, Nicola and Gattens, Michael and Jolley, Jennifer D and Liesner, Ri and Meacham, Stuart and Millar, Carolyn M and Nurden, Alan T and Peerlinck, Kathelijne and Perry, David J and Poudel, Pawan and Schulman, Sol and Schulze, Harald and Stephens, Jonathan C and Furie, Bruce and Robinson, Peter N and van Geet, Chris and Rendon, Augusto and Gomez, Keith and Laffan, Michael A and Lambert, Michele P and Nurden, Paquita and Ouwehand, Willem H and Richardson, Sylvia and Mumford, Andrew D and Freson, Kathleen},
  title     = {Human phenotype ontology annotation and cluster analysis to unravel genetic defects in 707 cases with unexplained bleeding and platelet disorders},
  series = {Genome Medicine},
  volume    = {7},
  journal   = {Genome Medicine},
  number    = {36},
  doi       = {10.1186/s13073-015-0151-5},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-143329},
  year      = {2015},
  abstract  = {Background: Heritable bleeding and platelet disorders (BPD) are heterogeneous and frequently have an unknown genetic basis. The BRIDGE-BPD study aims to discover new causal genes for BPD by high throughput sequencing using cluster analyses based on improved and standardised deep, multi-system phenotyping of cases. Methods: We report a new approach in which the clinical and laboratory characteristics of BPD cases are annotated with adapted Human Phenotype Ontology (HPO) terms. Cluster analyses are then used to characterise groups of cases with similar HPO terms and variants in the same genes. Results: We show that 60\% of index cases with heritable BPD enrolled at 10 European or US centres were annotated with HPO terms indicating abnormalities in organ systems other than blood or blood-forming tissues, particularly the nervous system. Cases within pedigrees clustered closely together on the bases of their HPO-coded phenotypes, as did cases sharing several clinically suspected syndromic disorders. Cases subsequently found to harbour variants in ACTN1 also clustered closely, even though diagnosis of this recently described disorder was not possible using only the clinical and laboratory data available to the enrolling clinician. Conclusions: These findings validate our novel HPO-based phenotype clustering methodology for known BPD, thus providing a new discovery tool for BPD of unknown genetic basis. This approach will also be relevant for other rare diseases with significant genetic heterogeneity.},
  language  = {en}
}